drugset
drugset / Trial / NCT02900027

Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides

NCT02900027 ↗

Phase 1 Completed 56 enrolled Ionis Pharmaceuticals, Inc. Akcea Therapeutics · collab
RandomizedParallel-groupDouble-blindOther

Summary

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APOC-III-LRx given to healthy volunteer subjects.

Timeline

Start
2016-09
Primary completion
2018-04-30
Completion
2018-04-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Olezarsen Antisense oligonucleotide 10 mg Subcutaneous
Comparator Olezarsen Antisense oligonucleotide 15 mg Subcutaneous
Comparator Olezarsen Antisense oligonucleotide 30 mg Subcutaneous
Comparator Olezarsen Antisense oligonucleotide 60 mg Subcutaneous
Comparator Olezarsen Antisense oligonucleotide 90 mg Subcutaneous
Comparator Olezarsen Antisense oligonucleotide 120 mg Subcutaneous

Indications

hypertriglyceridemia